INTRODUCTION
Miscarriage occurs in 10-20% of clinical pregnancies. 1 Missed abortion is defined as a pregnancy in which there is no embryo (empty sac) or unrecognized foetal death. Women experiencing a missed abortion generally have little or no bleeding and no other overt signs or symptoms. 2 It may also be referred to as blighted ovum, silent miscarriage, anembryonic or non-viable pregnancy, or foetal or embryonic demise. 3 Causes of such miscarriages include anembryonic gestation, foetal chromosomal abnormalities, maternal diseases, placental abnormalities, and uterine anomalies. Treatment options of missed miscarriage include expectant management (waiting for spontaneous expulsion), medical management (administration of misoprostol), surgical management (evacuation of the uterus under anaesthesia). The increased concern in deciding the mode of treatment is due to closed cervical os and possibility of adherence of products of conception to the uterine wall. Expectant management has a high failure rate and is associated with the emotional distress of carrying a nonviable fetus.
miscarriages, use of misoprostol alone without antiprogesterone is valid as level of progesterone declines due to foetal demise. 7 Medical management with misoprostol with its high expulsion rate has reduced the need of surgical evacuation. 8 Misoprostol can be administered by various routes and in different doses. The objective of this study was to compare the efficacy, outcome and side effects of sublingual and vaginal misoprostol for the medical management of missed miscarriage.
METHODS
This prospective randomized study was carried out in the department of obstetrics and gynecology, Kasturba hospital, New Delhi over a period of four months (May 2015 to August 2015). A total of fifty women diagnosed as missed miscarriage on pelvic examination and ultrasound were admitted. Missed miscarriage is characterized by closed cervix and minimal or no bleeding per vaginum. On ultrasound it is defined as an intrauterine gestational sac with a mean sac diameter of 25 mm or more with no visible embryonic pole, an embryonic pole of more than 7 mm with no cardiac activity or persistent absence of cardiac activity on a second scan at least 7 to 10 days later 9 Women with suspected ectopic pregnancy, excessive bleeding per vaginum, incomplete miscarriage, hemodynamically unstable, history of asthma, previous cesarean or allergy to prostaglandins were excluded from this study. We used and assigned blocks of four randomizations to two groups of participants. Gestational age was calculated from last menstrual period or ultrasonography. Complete history taking, physical examination, hemogram and coagulation profile were done. Women were explained about the medical and surgical management and written consent was taken. They were randomized to vaginal or sublingual route of drug administration by lottery method (random sampling). A total number of 25 cases in each of the two groups were considered. Women in group A received 400microg of misoprostol sublingually every four hours for a maximum of 5 doses and those in Group B received 400 microgram of misoprostol vaginally every four hours for a maximum of 5 doses. After misoprostol administration, pulse, blood pressure, and temperature were recorded at an interval of four hours. Women were observed for uterine contractions, bleeding per vaginum, and expulsion of fetus. If the patient had strong uterine contractions, per vaginum examination was done and next dose was decided accordingly. Side effects like nausea, vomiting, diarrhea, fever, and significant vaginal bleeding were noted and patients were provided with symptomatic treatment. Fever was defined as temperature more than 100 degrees F. Diarrhea and vomiting were recorded if more than two episodes occurred. Excessive blood loss (more than 500 ml) and the need for blood transfusion were also noted. 10 After expulsion, products of conception were examined. Structured proformas were filled with information regarding age, parity, gestational age, ultrasound findings, number of doses of misoprostol administered, induction to abortion interval, side effects, outcome of the treatment. Ultrasound was done to rule out retained products of conception in women who expelled. Incomplete miscarriage is when the intrauterine tissue diameter on ultrasound scan is ≥ 15 mm. 11 Primary outcome measure was complete expulsion of the products of conception without surgical intervention. Secondary outcome measures were failure of treatment, incomplete miscarriage, induction to abortion interval and side effects. Failure was defined as cases with incomplete or no dilatation within 12 hours of last dose of misoprostol. Induction abortion interval was defined as the time interval between administrations of first dose of misoprostol up to the time when the fetus was expelled. Surgical evacuation was considered for those who failed to abort after receiving 5 doses of misoprostol and those who had incomplete miscarriage. Cases were observed for 6 to 12 hours after surgical evacuation for bleeding per vaginum and vitals were monitored. Subjective assessment of the patients comfort was done during the time of discharge. Statistical analysis was performed by using software package Stata. Statistical analysis was done to assess the significance of variables and p-value less than 0.05 was considered as statistically significant. Table 1 shows the demographic Profile of the women diagnosed with missed abortion. It clearly depicts that there was no significant difference with respect to age, parity and mean gestational age between the two groups. Table 3 shows the side effects of misoprostol in both groups. Side effects were significantly more frequent in the sublingual group compared to the vaginal group. Diarrhoea was the major frequent side effect of sublingual misoprostol seen in 32% cases against only 12% cases with vaginal misoprostol. Table 4 shows the level of comfort of the patient during administration of the drug. Sublingual route was better accepted by the cases. 
RESULTS

DISCUSSION
Misoprostol is a synthetic prostaglandin E 1 analogue which is used for various indications like induction of abortions, medical management of miscarriage, cervical ripening before surgical procedures, induction of labour and management postpartum haemorrhage. 12 When used for medical management of missed miscarriage it can be administered orally, vaginally or sublingually. A number of studies have demonstrated that it is safe and efficient for achieving fetal expulsion. In our study both the groups were comparable with regards to age, parity and gestational age. Complete abortion rates achieved in both the groups are comparable to those observed in a study done by Sonsanoh et al in Thailand. 13 Tang Os et al 14 and Zhang J et al 15 observed a much higher complete abortion rate (87.5% and 88% respectively) than our study which may be attributed to the higher dose of misoprostol used in their study. Also, we subjected our cases to surgical evacuation if expulsion was not achieved with five doses; further repeat doses were not given which may also be the cause of low success rate. The difference in the complete miscarriage rates of first trimester missed miscarriages between the two groups was found to be statistically insignificant which was similar to that observed in the other studies as well. 14, 16 The induction to abortion interval was shorter in the sublingual group than the vaginal group but the difference was statistically insignificant. This may be due to the shortest time to peak concentration, highest peak concentration and greatest bioavailability of the sublingual administration of the drug. 17 Misoprostol is rapidly absorbed through the sublingual mucosa because of its rich blood supply and neutral pH of the buccal cavity. The induction to abortion interval is longer in the vaginal administration but has a similar successful abortion rate. This can be explained by the fact that although the peak concentration of misoprostol attained is lower by vaginal route but it is sustained at that level for a longer period of time. 18 In our study the side effects were significantly more frequent in the sublingual group as compared to the vaginal group. Unpleasant taste was commonly (60%) experienced by the women in sublingual group. Another study has reported a significantly increased frequency of unpleasant taste in women taking sublingual misoprostol. 19 Other side effects like diarrhea, shivering and fever were also more common in the sublingual group has also seen by Tang OS et al. 20 Increased incidence of fever with sublingual
